Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity

Nephrology Dialysis Transplantation

Volumn 11, Issue 5, 1996, Pages 881-884

  Low, C L ^a   Phelps, K R ^b   Bailie, G R ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

CAPD; Haemodialysis; Haemoperfusion; Management; NAPA; Procainamide; Toxicity

Indexed keywords

ACECAINIDE; ANTIARRHYTHMIC AGENT; PROCAINAMIDE;

AGED; ARTICLE; CASE REPORT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMOPERFUSION; HUMAN; KIDNEY FAILURE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0029960908     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027421     Document Type: Article

References (17)

1. Koch-Weser J. Pharmacokinetics of procainamide in a man. Ann NY Acad Sci 1979; 179: 370-382
2. Ludden TM, Crawford MH. N-acetylprocainamide kinetics after single and repeated oral doses. Clin Pharmacol Ther 1982; 31 (3): 343-349
3. Reidenberg MM, Drayer DE, Levy M et al. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 1975; 17(6): 722-730
4. Dutcher JS, Strong JM, Lucas SV et al. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. Clin Pharmacol Ther 1977; 22(4): 447-457
5. Rosansky SJ, Brady ME. Procainamide toxicity in a patient with acute renal failure. Am J Kidney Dis 1986; 6: 502-506
6. Gibson TP, Lowenthal DT, Nelson HA et al. Elimination of procainamide in end stage renal failure. Clin Pharmacol Ther 1975; 17(3), 321-329
7. Gibson TP, Atkinson AJ, Matusik E et al. Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 1977: 12: 422-429
8. Drayer DE. Lowemhal DT, Woosley RL et al. Accumulation of N-acetylprocainarnide, an active metabolite of procainamide. in patients with impaired renal function. Clin Pharmacol Ther 1977; 22(1): 63-69
9. Stec GP, Atkinson AJ, Nevin MJ et al. N-acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin Pharmacol Ther 1979, 26(5): 618-628
10. Olshansky B, Martins J, Hunt S. N-acetylprocainamide causing torsades de pointes Am J Cardiol 1982; 50: 1439-1441
11. Herre JM, Thompson JA. Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetylprocainamide. Am J Cardiol 1985; 55: 227-228
12. Villalba-Pimentel L, Epstein LM. Foster JR et al. Survival after massive procainamide ingestion. Am J Cardiol 1973; 32: 727-730
13. Kar PM, Kellner K, Ing TS et al. Combined high-efficiency hemodialysis and charcoal hemoperfusion in severe N-acetylprocainamide intoxication. Am J Kidney Dis 1992, 4: 403-406
14. Borkan SC, Hemoperfusion for N-acetylprocainamide intoxication Ann intern Med 1986; 105: 965-966 (Letter)
15. Braden GL, Fitzgibbons JP. Germain MJ et al. Hemoperfusion for treatment of N-acetylprocainamide intoxication. Ann Intern Med 1986; 105: 64-65
16. Atkinson AJ, Krumlovsky FA, Huang CM. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. Clin Pharmacol Ther 1976; 20(5): 585-592
17. Domoto DT, Brown WW, Bruggensmith P. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemodiafiltration. Ann Intern Med 1987; 106: 550-552